Zelira’s stock triples as cannabinoid outperforms Lyrica in pain May 31, 2023 By Tamra Sami Medicinal cannabis company Zelira Therapeutics Ltd.’s stock shot up 224% on May 31 on the heels of news that its cannabinoid product, ZLT-L-007, outperformed Lyrica (pregabalin, Pfizer Inc) in a head-to-head trial in diabetic nerve pain.Read More
